AR036208A1 - Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos - Google Patents

Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos

Info

Publication number
AR036208A1
AR036208A1 ARP020102942A ARP020102942A AR036208A1 AR 036208 A1 AR036208 A1 AR 036208A1 AR P020102942 A ARP020102942 A AR P020102942A AR P020102942 A ARP020102942 A AR P020102942A AR 036208 A1 AR036208 A1 AR 036208A1
Authority
AR
Argentina
Prior art keywords
preparation
compound
flibanserin
flibanserine
same
Prior art date
Application number
ARP020102942A
Other languages
English (en)
Spanish (es)
Inventor
Dubini Enrica Dr
Ezhaya Antoine Dr
Bombarda Carlo Dr
Original Assignee
Bidachem Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bidachem Spa filed Critical Bidachem Spa
Publication of AR036208A1 publication Critical patent/AR036208A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26Radicals substituted by carbon atoms having three bonds to hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP020102942A 2001-08-02 2002-08-02 Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos AR036208A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118593 2001-08-02
EP01130180 2001-12-19

Publications (1)

Publication Number Publication Date
AR036208A1 true AR036208A1 (es) 2004-08-18

Family

ID=26076670

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020102942A AR036208A1 (es) 2001-08-02 2002-08-02 Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos
ARP100102577A AR077416A2 (es) 2001-08-02 2010-07-15 Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP100102577A AR077416A2 (es) 2001-08-02 2010-07-15 Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos

Country Status (26)

Country Link
EP (2) EP1414816B1 (cg-RX-API-DMAC7.html)
JP (1) JP3822601B2 (cg-RX-API-DMAC7.html)
KR (1) KR100899297B1 (cg-RX-API-DMAC7.html)
CN (1) CN1288147C (cg-RX-API-DMAC7.html)
AR (2) AR036208A1 (cg-RX-API-DMAC7.html)
AT (1) ATE288911T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002331361B2 (cg-RX-API-DMAC7.html)
BR (1) BR0211601A (cg-RX-API-DMAC7.html)
CA (1) CA2450093C (cg-RX-API-DMAC7.html)
CO (1) CO5560572A2 (cg-RX-API-DMAC7.html)
DE (1) DE60202958T2 (cg-RX-API-DMAC7.html)
DK (1) DK1414816T3 (cg-RX-API-DMAC7.html)
EA (1) EA006400B1 (cg-RX-API-DMAC7.html)
ES (1) ES2237694T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20040107B1 (cg-RX-API-DMAC7.html)
HU (1) HU228666B1 (cg-RX-API-DMAC7.html)
IL (2) IL159151A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000913A (cg-RX-API-DMAC7.html)
MY (1) MY127294A (cg-RX-API-DMAC7.html)
NZ (1) NZ530510A (cg-RX-API-DMAC7.html)
PL (1) PL210224B1 (cg-RX-API-DMAC7.html)
PT (1) PT1414816E (cg-RX-API-DMAC7.html)
RS (1) RS50742B (cg-RX-API-DMAC7.html)
SI (1) SI1414816T1 (cg-RX-API-DMAC7.html)
UA (1) UA76767C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003014079A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA80135C2 (en) * 2002-05-22 2007-08-27 Boehringer Ingelheim Pharma Pharmaceutical composition containing flibanserin polymorph a
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
WO2007014929A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007099070A1 (en) * 2006-02-28 2007-09-07 Boehringer Ingelheim International Gmbh Treatment of prevention of valvular heart disease with flibanserin
RS54398B1 (sr) * 2006-05-09 2016-04-28 Sprout Pharmaceuticals, Inc. Upotreba flibanserina za lečenje poremećaja seksualne želje u postmenopauzi
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CN101505736A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
CA2672957C (en) 2006-12-20 2015-04-14 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN108699007A (zh) * 2016-01-31 2018-10-23 孟晓明 氟班色林的新晶型及其制备方法及其用途
CN111303043A (zh) * 2019-04-19 2020-06-19 武汉万知化工医药有限公司 一种氟班色林盐酸盐的制备方法
CN115919860B (zh) * 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
JP2004537597A (ja) 2004-12-16
HU228666B1 (en) 2013-05-28
ES2237694T3 (es) 2005-08-01
EA200400252A1 (ru) 2004-08-26
PL210224B1 (pl) 2011-12-30
CA2450093A1 (en) 2003-02-20
HRP20040107B1 (hr) 2012-02-29
MY127294A (en) 2006-11-30
JP3822601B2 (ja) 2006-09-20
HK1070063A1 (en) 2005-06-10
EA006400B1 (ru) 2005-12-29
BR0211601A (pt) 2004-08-24
DK1414816T3 (da) 2005-04-11
EP1414816B1 (en) 2005-02-09
HUP0401201A2 (hu) 2004-10-28
NZ530510A (en) 2004-07-30
DE60202958D1 (de) 2005-03-17
AU2002331361B2 (en) 2008-06-05
PT1414816E (pt) 2005-04-29
CA2450093C (en) 2008-09-23
IL159151A (en) 2009-09-22
KR20040023704A (ko) 2004-03-18
CN1288147C (zh) 2006-12-06
HRP20040107A2 (en) 2004-06-30
AR077416A2 (es) 2011-08-24
WO2003014079A8 (en) 2003-11-20
DE60202958T2 (de) 2006-04-06
PL364598A1 (en) 2004-12-13
CN1551879A (zh) 2004-12-01
RS50742B (sr) 2010-08-31
IL159151A0 (en) 2004-06-01
HUP0401201A3 (en) 2004-11-29
WO2003014079A1 (en) 2003-02-20
CO5560572A2 (es) 2005-09-30
EP1518858A1 (en) 2005-03-30
SI1414816T1 (en) 2005-06-30
KR100899297B1 (ko) 2009-05-26
UA76767C2 (uk) 2006-09-15
MXPA04000913A (es) 2004-10-27
YU7804A (sh) 2006-08-17
ATE288911T1 (de) 2005-02-15
EP1414816A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
AR036208A1 (es) Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
AR035603A1 (es) Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos
SE0104334D0 (sv) Therapeutic agents
UY26291A1 (es) Compuestos químicos xxii
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
WO2005077950A3 (en) Medicaments with hm74a receptor activity
WO2003004480A3 (en) Substituted piperazine and diazepanes as histamine h3 receptor agonists
JP2008531714A (ja) 不安障害の治療用及び/又は予防用の医薬組成物
SE0104340D0 (sv) New compounds
UY26290A1 (es) Compuestos químicos xxi
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
JP2004537597A5 (cg-RX-API-DMAC7.html)
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
AR028475A1 (es) Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
PA8571201A1 (es) Polimorfo del acido 4-[2-[4-[1-(2-etoxietil)-1h-bencimidazol-2-il]-1-piperidinil]etil]-alfa, alfa-dimetil-bencenoacetico
TWI250872B (en) Carbamate compounds for use in preventing or treating bipolar disorder
MX2009006454A (es) Derivados de espiro-piperidina.
MX2009005544A (es) Indoles.
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
ES2134709B1 (es) Utilizacion de los derivados de 1-(4-(4-aril (0 heteroaril)-1-piperazinil)-butil)-1h-azol para la preparacion de un medicamento destinado al tratamiento de los transtornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo en los m
AR037427A1 (es) Compuesto de quinolina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento para prepararlo y compuestos de quinolina de utilidad como intermediarios en dicho procedimiento
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones

Legal Events

Date Code Title Description
FC Refusal